Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Fei Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8329-0899; OpenAlex author ID A5100325775. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 3

  1. The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.jare.2025.10.079↗
  2. Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation. Last author DOI 10.1016/j.intimp.2025.114528↗
  3. [Progress in the diagnosis and treatment of pancreatic cancer with acute pancreatitis as the initial symptom]. Last author DOI 10.3760/cma.j.cn112139-20240418-00192↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wentong Mei · 2 shared papers, 2025–2026 · strength 0.53
  2. Yuchen Jia · 2 shared papers, 2025–2026 · strength 0.53
  3. Yixuan Ding · 1 shared paper, 2026 · strength 0.27
  4. Xiaoqing Xu · 1 shared paper, 2026 · strength 0.27
  5. Zheng Wang · 1 shared paper, 2025 · strength 0.26
  6. Chong-chong Gao · 1 shared paper, 2024 · strength 0.24
  7. R Jiang · 1 shared paper, 2024 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.